Miércoles 21 de Febrero 2018

Top Cancer Experts to Announce New England Initiative Combining Immuno-Oncology Clinical Trials and Molecular Science Through Genomics Supercomputing Infrastructure to Benefit Women and Pediatric Oncology Patients

The supercomputing genomics engine, a decade in the making, has
successfully completed analyses of more than 21,000 cancer tissue
samples analyzed for whole genome, whole exome and RNA from more than
7,000 unique patients with multiple tumor types—and with the world’s
largest database of human cancer whole genomes—enabled the discovery of
novel neoepitopes in cancer tissue for the development of neoepitope
antibodies and vaccines in the war against cancer

CULVER CITY, Calif. & BOSTON–(BUSINESS WIRE)–Cancer MoonShot 2020:

WHAT: Press Conference with Patrick Soon-Shiong, MD, CEO of
NantWorks and Founder of Cancer
MoonShot 2020
, and a panel that includes premier oncologists and
researchers, biotech and leaders from community oncologists New England
Cancer Specialists as well as other renowned experts. The panel will
present clinical results of novel neoepitope antibody trials to date and
how this multidisciplinary collaborative can help rapidly advance the
promise of personalized cancer vaccines for more patients.

ANNOUNCEMENT:

The collaboration with prominent Maine-based community oncologists New
England Cancer Specialists
 (NECS) represents the first personalized
immuno-oncology supercomputing collaboration to implement and support
the Centers for Medicare & Medicaid Services’ (CMS) new Oncology Care
Model (OCM) with patient and provider centric technology and
administrative support to provide higher quality, better coordinated
oncology in local communities and to ensure that 21st century treatments
are deployed by local community oncologists.

With successful completion of Phase II clinical trials of novel
neoepitope antibodies, clinical scientists from major academic centers
and collaborators under CRADA agreements with NCI will share findings
and discuss plans to leverage learnings to advance treatments for
women’s cancers, such as ovarian, as well as cancers affecting children.

DISCUSSION POINTS:

Together, they will discuss how advanced molecular science and
leading-edge technology are rapidly advancing immunotherapy as the next
generation of cancer care. Additionally, they will discuss a unique
collaboration with NECS who champion equitable access to the most
advanced cancer care possible to patients within their own
community. Among the key insights to be shared by Dr. Soon-Shiong and
his panelists are:

  • Advancements in immunotherapy enabled by artificial intelligence and
    advanced molecular science to provide oncologists with unprecedented
    insights to help identify personalized, cost-effective therapy
    strategies before treatment begins.
  • The development and understanding of novel neoepitope antibodies, and
    their role in finally achieving low toxicity, targeted cancer
    therapy—with the ultimate hope of accelerating FDA approvals of
    effective and safe cancer antibodies or vaccines.
  • The role of machine learning in the complex understanding of the
    cancer genome and how the Supercomputing Medical Reasoning Engine
    provides real-time predictive modeling and clinical outcomes that can
    continually improve physicians’ ability to make more effective care
    decisions.
  • How NECS and participating oncologists will leverage the
    Supercomputing Infrastructure and a suite of cutting-edge technology
    to meet OCM’s new targets for better care, smarter spending and
    healthier populations as well as accessing 21st century
    immuno-oncology clinical trials.
  • The use of the Supercomputing Genomics Engine to establish the world’s
    largest knowledge base of genomic and proteomic profile of brain
    tumors from children – The Brain Tumor Atlas.

WHO:

1. Patrick
Soon-Shiong
, MD, Founder and CEO, NantWorks, leader of the Cancer
MoonShot 2020 program

2. Philip
M. Arlen
, MD, CEO and Chief Medical Officer, Precision Biologics,
Inc. and Attending Physician at the Walter Reed Military Medical Center
and Medical Oncology Branch of the National Cancer Institute

3. Carla
Balch
, President, NantCare

4. Leonard
Sender
, MD, Executive Director Pediatric, Adolescent and Young Adult
Cancer Moonshot 2020

5. Richard
D. Kim
, MD, Associate Professor, Department of Gastrointestinal
Oncology and Medical Director, H. Lee Moffitt Cancer Center

6. Adam
C. Resnick
, PhD, Research Scientist, Department of Biomedical and
Health Informatics at The Children’s Hospital of Philadelphia

7. Giannoula
Lakka Klement
, MD, Chief, Academic and Research Affairs, Division of
Pediatric Hematology/Oncology, Director, Rare Tumors & Vascular
Anomalies Program; Assistant Professor, Tufts University School of
Medicine

8. Christian
A. Thomas
, MD, Director of Clinical Research, New England Cancer
Specialists

9. Tracey
F. Weisberg
, MD, President and Lead Physician, New England Cancer
Specialists

   

WHEN:

Wednesday, October 26, 11:00 a.m. – 1:30 p.m. ET
 

WHERE:

Hyatt Regency – Boston, Nantucket Room
1 Ave de Lafayette
Boston, MA 02111
 

CONTACT:

Dorit Baxter

NantHealth

401-871-0734

 

All Media Must RSVP and Be Credentialed to Attend

 

Photos from the event will be available on www.gettyimages.com

 

For more information on Dr. Patrick Soon-Shiong, Cancer MoonShot 2020
and QUILT, please visit:
http://www.nature.com/nature/journal/v537/n7619_supp/full/537S63a.html
http://jamanetwork.com/journals/jama/article-abstract/2551878
http://www.cbsnews.com/news/billionaire-doctor-fights-cancer-in-unconventional-way/

About NantWorks
NantWorks, LLC, founded by renowned
physician scientist and inventor of the first human nanoparticle
chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the
umbrella organization for the following entities: NantHealth,
NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital
and NantCloud. Fact-based and solution-driven, each of NantWorks’
division entities operates at the nexus of innovation and
infrastructure. The core mission of NantWorks is convergence and a
systems approach to human biology: to develop and deliver a diverse
range of technologies that accelerates innovation, broaden the scope of
scientific discovery, enhance ground-breaking research, and improve
healthcare treatment for those in need. NantWorks is building an
integrated fact-based, genomically and proteomically -informed,
personalized approach to the delivery of care and the development of
next generation diagnostics and therapeutics for life threatening
diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more
information please visit www.nantworks.com
and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About Cancer MoonShot 2020
The Cancer MoonShot 2020 program
is one of the most comprehensive cancer collaborative initiative
launched to date, seeking to accelerate the potential of combination
immunotherapy as the next generation standard of care in cancer
patients. This initiative aims to explore a new paradigm in cancer care
by initiating randomized Phase II trials in patients at all stages of
disease in 20 tumor types in 20,000 patients within the next 36 months.
These findings will inform Phase III trials and the aspirational
moonshot to develop an effective vaccine-based immunotherapy to combat
cancer by 2020. For more information, please visit www.cancermoonshot2020.org and
follow @MoonShot2020 on Twitter.

About NantCare
NantCare, a member of the NantWorks ecosystem
of companies, is committed to ensuring every cancer patient has access
to true immunotherapy clinical trials (QUILT) or optimized treatment
based on GPS Cancer Scan results. By organizing all relevant data and
making it available for the world, NantCare aims to spread
oncology-related intelligence to maximize support of patients,
physicians and life science companies. NantCare embraces life science
company partnerships and strives to developing treatments guided by
genomic, transcriptomic and quantitative proteomic data. By supporting
community oncology clinically and financially, NantCare is ensuring they
continue to serve the majority of cancer patients in the US.

Contacts

NantHealth
Dorit Baxter, 401-871-0734